Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other financing activities (2021 - 2026)

Kura Oncology (KURA) reported Other financing activities of $69000.0 for Q1 2026, down 51.75% year-over-year from $143000.0 in Q1 2025, and down 86.6% on a QoQ basis from $515000.0 in Q2 2025.

Kura Oncology (KURA) has 6 years of Other financing activities data on file, last reported at $69000.0 in Q1 2026.

  • Quarterly Other financing activities fell 51.75% year-over-year to $69000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 75.23% YoY) and the FY2025 annual result came in at $1.8 million, down 79.16% from the prior year.
  • Other financing activities fell to $69000.0 in Q1 2026 per KURA's latest filing, from $515000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $3.0 million in Q2 2024 and bottomed at $69000.0 in Q1 2026.
  • The 5-year median for Other financing activities is $567000.0 (2022), against an average of $1.1 million.
  • The widest annual swing landed in 2024, when Other financing activities surged 2521.43%; it then sank 94.4% in 2025.
  • Tracing KURA's Other financing activities over 5 years: stood at $567000.0 in 2022, then sank by 85.19% to $84000.0 in 2023, then jumped by 860.71% to $807000.0 in 2024, then slumped by 36.18% to $515000.0 in 2025, then plunged by 86.6% to $69000.0 in 2026.
  • Per Business Quant, the three latest KURA Other financing activities figures stand at $69000.0 (Q1 2026), $515000.0 (Q2 2025), and $143000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 69,000.00
Mar 31, 2026 69,000.00
Jun 30, 2025 515,000.00
Jun 30, 2025 515,000.00
Mar 31, 2025 143,000.00
Mar 31, 2025 143,000.00
Dec 31, 2024 807,000.00
Dec 31, 2024 807,000.00
Sep 30, 2024 2.20 Mn
Sep 30, 2024 2.20 Mn
Jun 30, 2024 3.04 Mn
Jun 30, 2024 3.04 Mn
Mar 31, 2024 2.56 Mn
Mar 31, 2024 2.56 Mn
Sep 30, 2023 84,000.00
Sep 30, 2023 84,000.00
Jun 30, 2023 431,000.00
Jun 30, 2023 431,000.00
Dec 31, 2022 567,000.00
Dec 31, 2022 567,000.00
Sep 30, 2022 880,000.00
Sep 30, 2022 880,000.00
Jun 30, 2022 2.67 Mn
Jun 30, 2022 2.67 Mn
Mar 31, 2022 303,000.00
Mar 31, 2022 303,000.00
Dec 31, 2021 794,000.00
Dec 31, 2021 794,000.00
Sep 30, 2021 2.26 Mn
Sep 30, 2021 2.26 Mn
Jun 30, 2021 545,000.00
Jun 30, 2021 545,000.00